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Resumo
A neurofibromatose tipo 1 é uma doença 
autossómica dominante em que o neurofibroma 
é a lesão mais característica. Os tumores 
malignos de nervo periférico são mais frequentes 
na neurofibromatose tipo 1 e podem resultar 
da transformação de neurofibromas, surgir 
de novo ou após-radioterapia. Existem várias 
características nos estudos imagiológicos, 
principalmente em Ressonância Magnética, 
que podem auxiliar na diferenciação de lesões 
benignas, como os neurofibromas, dos tumores 
malignos de nervo periférico, nomeadamente 
as dimensões, o aumento dimensional ao longo 
do tempo, a heterogeneidade de sinal com 
degenerescência quística ou o edema perilesional.
Descrevemos um caso de uma doente de 29 
anos com neurofibromatose tipo 1 com uma 
lesão no segmento proximal da coxa direita com 
crescimento ao longo de vários meses.  O estudo 
imagiológico e anatomopatológico da biópsia e 
após a cirurgia revelaram um tumor maligno da 
bainha do nervo periférico.
Palavras-chave
Neoplasia maligna do sistema nervoso 
periférico; Coxa; Neurofibromatose.
Abstract
Neurofibromatosis type 1 is an autosomal 
dominant disease, with neurofibroma being 
the hallmark of  this disease. Malignant 
peripheral nerve tumors are more frequent in 
neurofibromatosis type 1 and may result from 
the transformation of  neurofibromas, arising 
de novo or post-radiotherapy. There are several 
features in the imaging studies, primarily in 
Magnetic Resonance, that may help differentiate 
benign lesions, such as neurofibromas, from 
malignant peripheral nerve tumors, namely their 
larger dimensions, dimensional increase over 
time, signal heterogeneity with intratumoral 
cystic change or perilesional edema.
We report a case of  a 29-year-old patient with 
neurofibromatosis type 1 who presented 
with a lesion in the proximal right thigh with 
a progressive increase over several months. 
Imaging and pathologic studies of  the biopsy and 
post-chirurgic revealed a malignant tumor of  the 
peripheral nerve sheath. 
Keywords
Peripheral nervous system malignant neoplasm; 
Thigh; Neurofibromatosis.
Radiological Case Report / Caso Clínico
Case Report
A 29 years old female with the diagnosis of  neurofibromatosis 
type 1 and multiple neurofibromas scattered throughout their 
body complained of  a mass in the right thigh with progressive 
increase in size for several months. She also referred pain over 
the mass. Physical examination revealed a firm mass in the 
proximal right thigh. There were also other small cutaneous 
nodules over the entire body (probably neurofibromas) and 
several café-au-lait spots. Her blood tests were unremarkable. 
A CT (figure 1) was performed and showed a well-defined 
heterogeneous mass with cystic and solid components located 
lateral to the sartorius and rectus femoris and anterior to the 
vastus intermedius.
The Positron Emission Tomography–Computed Tomography 
(PET-CT) reveals an intense uptake of  the mass (figure 2).
On Magnetic Resonance images (figures 3 and 4) the mass 
was isointense to muscles in T1-weighted-images and 
heterogeneous high signal in T2-weighted-images. It has a 
fusiform shape and well-defined contours, without invasion of  
the adjacent muscles that were displaced by the mass effect 
of  the lesion. Administration of  gadolinium revealed solid 
and cystic areas. Note the enlargement of  the mass on the 
MR study performed 2 months after the CT. 
A tumor with origin in the peripheral nerve and with 
malignant nature was the most probable diagnosis. The 
pathologic studies of  the biopsy and the surgical specimen 
confirmed a malignant peripheral nerve tumor. The patient 
underwent surgery, but the margins were positive. Adjuvant 
radiotherapy and chemotherapy was then performed. 
On a follow-up CT performed 6 months after surgery, 
hepatic metastasis were detected without evidence of  local 
recurrence.
Discussion
Neurofibromatosis type 1 (NF1), or von Recklinghausen 
disease, is an autosomal dominant disorder due to a 
mutation or deletion of  the NF1 gene on chromosome 17 
and it affects multiple organ systems.1
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Figure 1 – Computed Tomography (CT) 
of  the proximal thighs. Axial non-enhanced 
image (a) shows a low attenuation mass (red 
arrow) on the muscular plane of  the proximal 
right thigh lateral to the sartorius (S) and 
rectus femoris (RF) and anterior to the vastus 
intermedius (VI). Axial contrast enhanced 
image (b) reveals solid (red arrow) and cystic 
(blue arrow) componentes of  the mass. 
Coronal contrast enhanced image (c) shows 
that the mass has a fusiform shape with well-
defined contours.
Figure 2 – Positron emission tomography–
computed tomography (PET-CT) images 
show an intense uptake of  the mass (arrow) 
with SUVmax=11,17. Note the smaller 
and with lower uptake lesions (arrowheads) 
compatible with neurofibromas.
Figure 3 – Magnetic Resonance (MR) images 
of  the proximal thighs. Axial T1-weighted-
image (a) showing a mass (arrow) with 
intensity similar to that of  muscle. Note 
also small hyperintense areas (arrowhead), 
probably reflecting hemorrhagic foci. Axial 
T2-weighted-image (b) reveals heterogeneous 
high signal of  the mass (arrow). Coronal 
T1-weighted-image (c) shows that the mass 
(arrow) has a fusiform shape with well-defined 
contours and a rim of  fat (arrowheads). 
Coronal T2-SPAIR image (d) reveals small 
perilesional area (arrow).
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Neurofibromas, which are benign peripheral nerve sheath 
tumors, are the hallmark of  NF1.1 Three subtypes of  
neurofibromas have been described: localized, diffuse, and 
plexiform.2 The localized subtype is the most common 
(90%) and predominantly occur in patients without NF1, 
only up to 10% are associated with NF1.1,2,3 The diffuse 
subtype is relatively rare and most commonly affects 
children and young adults.4 Plexiform neurofibromas 
are pathognomonic of  NF1, occurring in up to 40% of  
patients with NF1 and frequently appears in childhood.1
On ultrasound, localized neurofibroma is a homogeneous, 
hypoechoic mass that may simulate a cyst. On CT 
neurofibromas are well-defined, hypodense masses with 
little or no enhancement. Classic MR imaging findings 
include a fusiform shape with tapered ends, low-to 
intermediate signal intensity on T1-weighted-images and 
high signal intensity on T2-weighted-images, a target 
sign (high signal intensity in the periphery and low signal 
intensity in the central region of  the lesion on T2-weighted-
images) or fascicular sign (multiple small hypointense foci 
interspersed within a hyperintense area on T2-weighted-
images).3
Imaging features most suggestive of  diffuse neurofibromas 
are a plaquelike or infiltrative lesion isointense or mildly 
hyperintense on T1-weighted-images and hyperintense on 
T2-weighted-images with intense enhancement.4
Plexiform neurofibromas present as multinodular confluent 
masses and thickening of  a long segment of  the nerve and 
its branches with low-attenuation on CT and hyperintense 
on fat-suppressed T2-weighted-images often with multiple 
target signs.2,3
Malignant peripheral nerve sheath tumors (MPNST) are 
malignant neoplasms that have origin in peripheral nerves 
or demonstrate peripheral nerve differentiation. About 
40%–60% of  MPNST originates from patients with NF1 
and present earlier (median age between 20 and 40 years) 
than sporadic ones (median age between 30 and 60 years).5,6 
MPNST arise from plexiform neurofibromas, de novo or 
secondary to radiation therapy and most commonly in 
the deep soft tissues.5 The life time risk of  developing a 
MPNST in patients with NF-1 is high, about 8% to 13%.6
The clinical presentation MPNST include a mass with more 
than 2cm, rapid growth, pain and neurological symptoms 
such as weakness or paresthesia’s.5,6
On imaging studies, MPNST usually present as a large 
(>5 cm), fusiform, heterogeneous soft tissue mass that 
Figure 4 - Magnetic Resonance 
(MR) axial T1-SPIR image (a) 
and coronal T1 weighted-image 
(b) of  the proximal thighs after 
gadolinium administration 
reveals a heterogeneous 
uptake of  the mass with solid 
(arrowheads) and cystic (arrows) 
areas.
may demonstrate ill-defined margins.3,7,8,9 On unenhanced 
CT, MPNST have low attenuation and heterogeneous 
enhancement after the administration of  iodate contrast.7 
These tumors have an intense uptake on PET-TC that is 
usually more intense than neurofibromas.7
A common diagnostic dilemma is that MPNSTs and 
neurofibromas may appear indistinguishable on imaging 
studies; however, there are several MR features that are 
useful for distinguishing them.8,9 Wasa et al described the 
MR features that are useful for distinguishing malignant 
peripheral nerve sheath tumors from neurofibromas: 
tumor size, presence of  peripheral enhanced pattern 
on gadolinium-enhanced T1-weighted images, presence 
of  perilesional edema-like zone and intratumoral cystic 
change.8 The presence of  two or more of  the four features 
suggestive of  malignancy indicate malignant peripheral 
nerve sheath tumor with a sensitivity of  61% and a 
specificity of  90%.8 Heterogeneity on T1-weighted images 
was also significant in differentiating neurofibroma from 
malignant peripheral nerve sheath tumor.8 
In our case, the lesion had most of  the above described 
features, namely, a large dimension, enlargement over time, 
heterogeneity on T1-weighted-images, intratumoral cystic 
change and perilesional edemalike zone.
MPNST has poor prognosis with 5-year survival ranging 
between 30% and 60%.10 The prognosis is worse for 
MPNST arising in the setting of  NF1 compared with 
sporadic disease.6,10 Large tumor size at presentation 
(typically >5 cm), positive surgical margins, high pathologic 
grade (G3) and metastatic disease are the most important 
adverse prognostic factors.10
The treatment for localized disease is surgical resection.6 
Adjuvant radiation therapy may be performed in selected 
cases such as when the surgical margins are positive.6,10 
Neoadjuvant chemotherapy may be beneficial in localized 
disease.6 In advanced or metastatic disease chemotherapy 
is performed, but outcomes are generally poor.6 There 
are several molecular agents under clinical trials and the 
targeting of  molecular pathways like TOR and hsp90 may 
change the course of  patient care.6
In conclusion, it is very important for the radiologist to be 
aware of  the imaging findings of  the neurofibromas and 
MPNST in patients with NF1.
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